Virbac stock holds after 2025 results and 2026 outlook

Virbac (FR0000031577) stock is anchored by the companys 2025 financial year, which delivered EUR 1.19 billion in revenue and EUR 140.7 million in EBITDA, with EBITDA margin at 11.8%. The group also reported net profit of EUR 73.6 million and proposed a dividend of EUR 1.45 per share for 2025, giving investors a clear base for the 2026 trading year.

2025 revenue reached EUR 1.19 billion

In its 2025 annual results, Virbac said revenue rose 6.3% at constant exchange rates and 5.4% on a reported basis to EUR 1.19 billion, a comparison that matters because it shows growth held up across currencies and not only in local terms. EBITDA climbed to EUR 140.7 million from the prior year, and the 11.8% margin gives a direct read on profitability after a year of expansion.

Net profit of EUR 73.6 million in 2025 adds another quantified checkpoint for the group, while the EUR 1.45 dividend underlines that the balance sheet and cash generation still supported shareholder returns. For a veterinary health company, the combination of revenue growth, margin and earnings is more useful than any single line item.

Margin at 11.8%

The 11.8% EBITDA margin in 2025 is the number that frames the next phase of the story. It tells the market how much room Virbac has for investment, pricing discipline and product mix changes in 2026.

Virbac also outlined 2026 guidance: management expects revenue growth of between 4% and 6% at constant exchange rates, while EBITDA margin is forecast to improve to around 12.5% of revenue. That is a quantified improvement of roughly 0.7 percentage point versus the 11.8% margin reported for 2025.

2026 guidance improves

The guidance range matters because it links growth to margin expansion rather than pure top-line momentum. A 4% to 6% revenue target and a 12.5% EBITDA margin imply that Virbac is trying to turn a solid 2025 into a more efficient 2026.

The same release also gives investors a dated management anchor for the current year, since the figures were published with the annual results for 2025 and the outlook for 2026. That combination of historical results and forward guidance is the central stock-market reference point for Virbac stock today.

Veterinary products carry growth

Virbacs product portfolio remains the operational driver behind those numbers, with companion animal, food-producing animal and specialty products forming the core of the business. The companys annual report framework shows why revenue is diversified across species and geographies rather than tied to a single line.

Because the 2025 release already includes the revenue, EBITDA, net profit and dividend figures, the product discussion is best read as a support layer rather than a separate thesis. Investors now have a clean baseline for monitoring whether 2026 can deliver the guided margin lift.

Virbac stock near its 2026 base

On 17 July 2026, Virbac stock remains a function of the 2025 earnings base and the 2026 guidance set out by management. The article uses EUR because the company reports in euros and the annual figures are the most relevant dated market-reference numbers available in this call.

Virbac stock data